A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Recruiting · Phase 2 · NCT06172478
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 12
- Sites paid
- 17
- Planned or actual enrollment
- 740
About the trial
- Sponsor
- Daiichi Sankyo (with Merck Sharp & Dohme LLC)
- Tested
- HER3-DXd (drug)
- Dates
- Started 2024-02-26; completion 2028-10-10
- Results posted
- Not yet
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carcinomas of the head and neck (SCCHN), HER2-negative gastric cancer ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, prostate cancer, second-line gastric cancer, lung cancer, and breast cancer.
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $1.7M in research payments for this study in 2025 (1,007 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dani R. Castillo, MD Medical Oncology · Duarte, CA
- Aarti K. Bhatia, M.B.B.S. Medical Oncology · New Haven, CT
- Guru P. Sonpavde, MD Medical Oncology · Orlando, FL
- Vincent Lam, M.D. Medical Oncology · Baltimore, MD
- Timothy G. Larson, M.D. Hematology & Oncology · Minneapolis, MN
- Douglas R. Adkins, MD Medical Oncology · Saint Louis, MO
- Christos Fountzilas, M.D. Medical Oncology · Buffalo, NY
- Rutika Mehta, MD, MPH Hematology & Oncology · New York, NY
- James W. Smithy, MD Hematology & Oncology · New York, NY
- Meredith A. Mckean, M.D. Hematology & Oncology · Nashville, TN
- Funda Meric, M.D. General Surgery · Houston, TX
- Andrew L. Coveler, MD Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute $755,920
- City of Hope National Medical Ctr $274,383
- David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $137,915
- Dana-Farber Cancer Institute $122,624
- Johns Hopkins University $80,264
- Healthpartners Institute $74,525
- Adventhealth Orlando, FL $73,366
- Health Research, Inc. $54,763
- University of Washington Medical Ctr, WA $48,049
- Ut MD Anderson Cancer Center $16,579
- Washington University $11,872
- Scri Oncology PArtners $7,229
- Johns Hopkins Hospital, the, MD $4,008
- Yale University $2,453
- Adventhealth Celebration $1,236
- Memorial Sloan Kettering Cancer Center $383
- Moffitt Cancer Center $90
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.